These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 19805668)

  • 1. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
    J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
    Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
    Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract.
    Huang MJ; Jiang Y; Liu WP; Li ZP; Li M; Zhou L; Xu Y; Yu CH; Li Q; Peng F; Liu JY; Luo F; Lu Y
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):166-74. PubMed ID: 17919841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
    Ma X; Guo Y; Pang Z; Wang B; Lu H; Gu YJ; Guo X
    Radiother Oncol; 2009 Dec; 93(3):492-7. PubMed ID: 19782419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy.
    Li YX; Liu QF; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Liu XF; Zhou LQ; Yu ZH
    Cancer; 2011 Nov; 117(22):5203-11. PubMed ID: 21523771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.
    Li YX; Wang H; Jin J; Wang WH; Liu QF; Song YW; Wang ZY; Qi SN; Wang SL; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1809-15. PubMed ID: 21470789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extranodal NK/T-cell lymphoma, nasal type: report of 15 cases.
    Tababi S; Kharrat S; Sellami M; Mamy J; Zainine R; Beltaief N; Sahtout S; Besbes G
    Eur Ann Otorhinolaryngol Head Neck Dis; 2012 Jun; 129(3):141-7. PubMed ID: 22321911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
    Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
    Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.